SAB Biotherapeutics is a clinical-stage biopharmaceutical company that develops human immunoglobulin G therapies for immune and autoimmune disorders using its proprietary Tc-Bovine platform, which leverages transchromosomal cattle to produce fully human antibodies without requiring human donors or convalescent plasma. The company's lead program, SAB-142, is a multi-specific anti-thymocyte globulin in clinical development for type 1 diabetes, designed to preserve insulin-producing beta cells by modulating autoreactive T cells, with clinical validation from established rabbit ATG therapies and early trial data demonstrating improved safety profiles. The company generates revenue through the development and eventual commercialization of its proprietary hIgG therapies, leveraging its competitive advantages in polyclonal antibody production and its portfolio of patents covering the Tc-Bovine platform and monoclonal antibody compositions, while maintaining manufacturing infrastructure and research capabilities to support its pipeline expansion into additional autoimmune indications.